Clinical trial
Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With…
NCT00418847 · The Hospital for Sick Children, Other · Completed
Key facts
| NCT number | NCT00418847 |
|---|---|
| Title | Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis |
| Official title | Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses |
| Lead sponsor | The Hospital for Sick Children, Other |
| Collaborators | Actelion Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gangliosidoses GM2 |
| Intervention type | Drug |
| Interventions | miglustat |
| Enrollment | 5 |
| Start date | Jul 1, 2004 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 5, 2007 |
| Last update posted | May 19, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: